New drug combo aims to slow lung damage in scleroderma patients
NCT ID NCT06297096
First seen Apr 12, 2026 · Last updated May 05, 2026 · Updated 2 times
Summary
This study tests whether combining two drugs, nintedanib and tocilizumab, works better than standard treatments for people with systemic sclerosis (scleroderma) who also have lung scarring. About 86 adults will receive either the combination or usual care for 56 weeks. The main goal is to see if the combo helps preserve lung function better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centrum Wsparcia Badań Klinicznych
RECRUITINGWarsaw, Masovian Voivodeship, 02-637, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.